PEN · XBRL financial data

Penumbra financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PEN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	560	748	847	1,059	1,195	1,404
Cost of revenue	222	272	312	376	440	461
Gross profit	338	475	535	683	755	942
Selling, general and administrative	287	378	450	506	574	663
Total operating expenses	377	483	529	609	746	753
Operating income (loss)	(39)	(8)	6	74	9	189
Interest income	—	3	2	7	14	16
Interest expense	—	2	2	2	1	1
Other income (expense)	(0)	(4)	(2)	1	(1)	1
Income tax expense (benefit)	(19)	(13)	6	(11)	7	27
Net income (loss)	(16)	5	(2)	91	14	178
Earnings per share, basic USD per share	(0.44)	0.14	(0.05)	2.37	0.36	4.57
Earnings per share, diluted USD per share	(0.44)	0.14	(0.05)	2.32	0.36	4.52
Weighted average shares, basic millions of shares	36	37	38	38	39	39
Weighted average shares, diluted millions of shares	36	38	38	39	39	39

Fiscal years (PEN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	70	59	70	167	324	187
Marketable securities	195	195	118	122	16	358
Accounts receivable	115	134	203	202	168	190
Inventory	220	264	334	388	407	432
Prepaid and other current assets	19	29	30	36	37	50
Total current assets	618	681	756	915	951	1,217
Property and equipment, net	48	59	65	73	63	117
Right-of-use asset	41	132	193	189	178	174
Goodwill	8	166	166	166	166	167
Total assets	823	1,244	1,371	1,556	1,533	1,827
Accounts payable	14	13	27	27	31	35
Accrued liabilities	86	100	106	111	112	132
Total current liabilities	106	123	145	151	158	183
Lease liability, non-current	44	137	199	197	187	183
Total liabilities	185	290	372	377	382	399
Retained earnings	41	46	44	135	60	238
Total stockholders' equity	641	954	999	1,179	1,151	1,428
Total liabilities and equity	823	1,244	1,371	1,556	1,533	1,827
Common shares outstanding (cover page) millions of shares	36	38	38	39	39	39

Fiscal years (PEN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(16)	5	(2)	91	14	178
Stock-based compensation	26	66	37	51	46	59
Depreciation and amortization	13	16	24	27	24	17
Net cash from operating activities	(33)	10	(56)	97	168	239
Purchases of property and equipment	25	21	19	15	21	64
Net cash from investing activities	(104)	(22)	55	(16)	78	(405)
Proceeds from issuing common stock	135	0	0	—	—	—
Share repurchases	—	—	0	0	100	0
Net cash from financing activities	135	1	12	16	(87)	27
Net change in cash	(3)	(10)	10	98	157	(138)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Penumbra	254	410	42*	39.4M	Q3 FY26 10-QSep 30, 2026
Align Technology	1,103	1,056	193*	71.0M	Q2 FY26 10-QJun 30, 2026
Medline	2,327	7,685	715*	not reported	Q2 FY26 10-QJun 27, 2026
Solventum	403	2,209	227*	170.2M	Q2 FY26 10-QJun 30, 2026
Hologic	2,168	1,048	230	223.2M	Q1 FY26 10-QDec 27, 2025
Globus Medical	508	790	210*	134.3M	Q2 FY26 10-QJun 30, 2026
MSA Safety	187	536	82*	38.5M	Q3 FY26 10-QSep 30, 2026
West Pharmaceutical Services	464	875	190*	69.7M	Q3 FY26 10-QSep 30, 2026
GLAUKOS	162	211	39*	59.2M	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.